Hemophilia: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Factor 8== | == Factor 8 == | ||
(weight in kg) x (50ml plasma/kg) x (desired F8 level - native F8 level) = total units | (weight in kg) x (50ml plasma/kg) x (desired F8 level - native F8 level) = total units^ | ||
'''Recommended Factor VIII Therapy for Specific Problems in Hemophilia''' | |||
''' | |||
{| border="1" cellpadding="2" | {| border="1" cellpadding="2" | ||
|- | |||
! align="left" | TYPE OF BLEEDING | ! align="left" | TYPE OF BLEEDING | ||
! align="left" | INITIAL DOSAGE | ! align="left" | INITIAL DOSAGE | ||
| Line 28: | Line 25: | ||
|- | |- | ||
| align="left" | Superficial | | align="left" | Superficial | ||
| align="left" | | | align="left" | <br/> | ||
| align="left" | | | align="left" | <br/> | ||
| align="left" | | | align="left" | <br/> | ||
|- | |- | ||
| align="left" | Deep | | align="left" | Deep | ||
| Line 38: | Line 35: | ||
|- | |- | ||
| align="left" | Nasal epistaxis | | align="left" | Nasal epistaxis | ||
| align="left" | | | align="left" | <br/> | ||
| align="left" | | | align="left" | <br/> | ||
| align="left" | | | align="left" | <br/> | ||
|- | |- | ||
| align="left" | Spontaneous | | align="left" | Spontaneous | ||
| Line 92: | Line 89: | ||
|- | |- | ||
| align="left" | Gastrointestinal severe bleeding | | align="left" | Gastrointestinal severe bleeding | ||
| align="left" | | | align="left" | <br/> | ||
| align="left" | | | align="left" | <br/> | ||
| align="left" | | | align="left" | <br/> | ||
|- | |- | ||
| align="left" | Neck/sublingual | | align="left" | Neck/sublingual | ||
| align="left" | | | align="left" | <br/> | ||
| align="left" | | | align="left" | <br/> | ||
| align="left" | | | align="left" | <br/> | ||
|- | |- | ||
| align="left" | Retroperitoneal | | align="left" | Retroperitoneal | ||
| align="left" | | | align="left" | <br/> | ||
| align="left" | | | align="left" | <br/> | ||
| align="left" | | | align="left" | <br/> | ||
|- | |- | ||
| align="left" | Intra-abdominal | | align="left" | Intra-abdominal | ||
| align="left" | | | align="left" | <br/> | ||
| align="left" | | | align="left" | <br/> | ||
| align="left" | | | align="left" | <br/> | ||
|- | |- | ||
| align="left" | Major trauma | | align="left" | Major trauma | ||
| align="left" | | | align="left" | <br/> | ||
| align="left" | | | align="left" | <br/> | ||
| align="left" | | | align="left" | <br/> | ||
|- | |- | ||
| align="left" | Head injury (see text) | | align="left" | Head injury (see text) | ||
| align="left" | | | align="left" | <br/> | ||
| align="left" | | | align="left" | <br/> | ||
| align="left" | | | align="left" | <br/> | ||
|- | |- | ||
| align="left" | Central nervous system bleeding (see text) | | align="left" | Central nervous system bleeding (see text) | ||
| align="left" | | | align="left" | <br/> | ||
| align="left" | | | align="left" | <br/> | ||
| align="left" | | | align="left" | <br/> | ||
|- | |- | ||
| align="left" | Surgical procedure | | align="left" | Surgical procedure | ||
| align="left" | | | align="left" | <br/> | ||
| align="left" | | | align="left" | <br/> | ||
| align="left" | | | align="left" | <br/> | ||
|} | |} | ||
{| width="100%" | {| width="100%" | ||
| align="left" | | |- | ||
| align="left" | | |||
CT, computed tomography | CT, computed tomography | ||
|} | |} | ||
''' | ''' Dosage of Factor VIII (Antihemophilic Factor)''' | ||
{| border="1" cellpadding="2" | {| border="1" cellpadding="2" | ||
|- | |||
! align="left" | BLEEDING RISK | ! align="left" | BLEEDING RISK | ||
! align="left" | DESIRED FACTOR VIII LEVEL (%) | ! align="left" | DESIRED FACTOR VIII LEVEL (%) | ||
| Line 158: | Line 158: | ||
{| width="100%" | {| width="100%" | ||
| align="left" | | |- | ||
| align="left" | | |||
Standard Calculation | Standard Calculation | ||
{| | {| | ||
|- | |- | ||
| width="2" | | | width="2" | <br/> | ||
| width="4%" valign="top" | '''2.''' | | valign="top" width="4%" | '''1.''' | ||
| In emergency therapy, the present level of factor VIII is assumed to be zero.<br /> | | Patient's plasma volume (50 mL/kg × weight in kg) × (Desired level of factor VIII [percent]) − (Present level of factor VIII [percent]) = Number of units for initial dose.<br/> | ||
|- | |||
| width="2" | <br/> | |||
| valign="top" width="4%" | '''2.''' | |||
| In emergency therapy, the present level of factor VIII is assumed to be zero.<br/> | |||
|- | |- | ||
| width="2" | | | width="2" | <br/> | ||
| width="4% | | valign="top" width="4%" | '''3.''' | ||
| One unit is the activity of the coagulation factor present in 1 mL of normal human plasma.<br /> | | One unit is the activity of the coagulation factor present in 1 mL of normal human plasma.<br/> | ||
|- | |- | ||
| width="2" | | | width="2" | <br/> | ||
| width="4% | | valign="top" width="4%" | '''4.''' | ||
| Because the half-life of factor VIII is 8–12 hr, the desired level is maintained by giving half the initial dose every 8–12 hr.<br /> | | Because the half-life of factor VIII is 8–12 hr, the desired level is maintained by giving half the initial dose every 8–12 hr.<br/> | ||
|- | |- | ||
| width="2" | | | width="2" | <br/> | ||
| width="4% | | valign="top" width="4%" | '''5.''' | ||
| Cryoprecipitate is assumed to have 80–100 U of factor VIII:C per bag; factor VIII:C concentrates list the units per bottle on the label. | | Cryoprecipitate is assumed to have 80–100 U of factor VIII:C per bag; factor VIII:C concentrates list the units per bottle on the label. | ||
|} | |} | ||
|} | |} | ||
==Factor 9== | == Factor 9 == | ||
(weight in kg) x (100ml plasma/kg) x (desired F9 level - native F9 level) = total units^ | (weight in kg) x (100ml plasma/kg) x (desired F9 level - native F9 level) = total units^ | ||
| Line 192: | Line 195: | ||
^^DDAVP is not helpful in F9 deficiency | ^^DDAVP is not helpful in F9 deficiency | ||
==Source== | == Source == | ||
DONALDSON 10/08 (From "Kaji Questions"), Rosen's | DONALDSON 10/08 (From "Kaji Questions"), Rosen's | ||
[[Category:Heme/Onc]] | |||
Revision as of 05:20, 12 March 2011
Factor 8
(weight in kg) x (50ml plasma/kg) x (desired F8 level - native F8 level) = total units^
Recommended Factor VIII Therapy for Specific Problems in Hemophilia
| TYPE OF BLEEDING | INITIAL DOSAGE | DURATION | COMMENT |
|---|---|---|---|
| Skin | |||
| Abrasion | None | None | Treat with local pressure and topical thrombin |
| Laceration | Usually none; if necessary, treat as minor | None | Local pressure and anesthetic with epinephrine may benefit; watch 4 hours after suturing; reexamine in 24 hours |
| Superficial | |||
| Deep | Minor bleeding (12.5 mg/kg) | Single-dose coverage | May need hospitalization for observation; repeat may be necessary for suture removal |
| Nasal epistaxis | |||
| Spontaneous | Usually none; may need to be treated as mild bleeding | None | Uncommon; consider platelet inhibition; treat in usual manner |
| Traumatic | Moderate bleeding (25 mg/kg) | Up to 5–7 days | Trauma-related bleeding can be significant |
| Oral | |||
| Mucosa or tongue bites | Usually none; treat as minor if persists | Single dose | Commonly seen |
| Traumatic (laceration) or dental extraction | Moderate (25 U/kg) to severe (50 U/kg) | Single dose; may need more | Saliva rich in fibrin lytic activity; oral ε-aminocaproic acid (Amicar) may be given at 100 mg every 6 hr for 7 days to block fibrinolysis; check contraindications; hospitalize patients with severe bleeding |
| Soft tissue/muscle hematomas | Moderate (25 U/kg) to severe (50 U/kg) | 2–5 days | May be complicated by local pressure on nerves or vessels (e.g., iliopsoas, forearm, calf) |
| Hemarthrosis | |||
| Early | Mild (12.5 U/kg) | Single dose | Treat as earliest symptom (pain); knee, elbow, ankle more common |
| Late or unresponsive cases of early hemarthrosis | Mild to moderate (25 U/kg) | 3–4 days | Arthrocentesis rarely necessary and only with 50% level coverage; immobilization is critical point of therapy |
| Hematuria | Mild (12.5 U/kg) | 2–3 days | Urokinase, the fibrinolytic enzyme, is in urine; with persistent hematuria an organic cause should be ruled out |
| Major bleeding | Major bleeding (50 U/kg) | 7–10 days or 3–5 days after bleeding ceases | In head trauma, therapy should be given prophylactically; early CT scan of head recommended for all |
| Gastrointestinal severe bleeding | |||
| Neck/sublingual | |||
| Retroperitoneal | |||
| Intra-abdominal | |||
| Major trauma | |||
| Head injury (see text) | |||
| Central nervous system bleeding (see text) | |||
| Surgical procedure | |||
|
CT, computed tomography |
Dosage of Factor VIII (Antihemophilic Factor)
| BLEEDING RISK | DESIRED FACTOR VIII LEVEL (%) | INITIAL DOSE (U/KG) |
|---|---|---|
| Mild | 5–10 | 12.5 |
| Moderate | 20–30 | 25 |
| Severe | 50 or greater | 50 |
|
Standard Calculation
|
Factor 9
(weight in kg) x (100ml plasma/kg) x (desired F9 level - native F9 level) = total units^
^half this dose should be readministered in 24 hours
^^DDAVP is not helpful in F9 deficiency
Source
DONALDSON 10/08 (From "Kaji Questions"), Rosen's
